Figure 4 : The progression free survival of the 2 risk subgroups of both groups.

Kaplan–Meier curves showing a non-significant difference in progression free survival between patients of intermediate risk treated with intravesical BCG (group I) and patients who received docetaxel (group II) or those of high risk patients of the 2 groups.

Essa et al.Journal of Cancer Therapeutics and Research  2016 5:6DOI : 10.7243/2049-7962-5-6